Journal for ImmunoTherapy of Cancer: 10 (4)

Basic tumor immunology

Original research: Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up (28 April, 2022)
Eva Oswald, Daniel Bug, Anne Grote, Kanstantsin Lashuk, Nassim Bouteldja, Dorothee Lenhard, Anne Löhr, Anke Behnke, Volker Knauff, Anna Edinger, Kerstin Klingner, Simone Gaedicke, Gabriele Niedermann, Dorit Merhof, Friedrich Feuerhake, Julia Schueler
Original research: Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy (28 April, 2022)
Xiaoming Liu, Carson A Wills, Longgui Chen, Jiawen Zhang, Yuanjun Zhao, Mi Zhou, Jeffrey M Sundstrom, Todd Schell, Vladimir S Spiegelman, Megan M Young, Hong-Gang Wang
Original research: Local anesthetics elicit immune-dependent anticancer effects (28 April, 2022)
Lucillia Bezu, Alejandra Wu Chuang, Allan Sauvat, Juliette Humeau, Wei Xie, Giulia Cerrato, Peng Liu, Liwei Zhao, Shuai Zhang, Julie Le Naour, Jonathan Pol, Peter van Endert, Oliver Kepp, Fabrice Barlesi, Guido Kroemer
Original research:
Cancer stem-like cells evade CD8⁺CD103⁺ tumor-resident memory T (T_RM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model
(13 April, 2022)
Stéphanie Corgnac, Isabelle Damei, Gwendoline Gros, Aziza Caidi, Stéphane Terry, Salem Chouaib, Marc Deloger, Fathia Mami-Chouaib
Original research: New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis (8 April, 2022)
Shuichi Shinohara, Yusuke Takahashi, Hiroyasu Komuro, Takuya Matsui, Yusuke Sugita, Ayako Demachi-Okamura, Daisuke Muraoka, Hirotomo Takahara, Takeo Nakada, Noriaki Sakakura, Katsuhiro Masago, Manami Miyai, Reina Nishida, Shin Shomura, Yoshiki Shigematsu, Shunzo Hatooka, Hajime Sasano, Fumiaki Watanabe, Katsutoshi Adachi, Kazuya Fujinaga, Shinji Kaneda, Motoshi Takao, Takashi Ohtsuka, Rui Yamaguchi, Hiroaki Kuroda, Hirokazu Matsushita
Original research: Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL (1 April, 2022)
Tingting Zhang, Hengqi Liu, Lei Jiao, Zhenzhen Zhang, Jin He, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Wenchen Gong, Bin Meng, Xiubao Ren, Huilai Zhang, Xianhuo Wang

Case report

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept (5 April, 2022)
Lee S Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, Baptiste Abbar, Bruno Pinna, Yves Allenbach, Jean-Paul Mira, Javid Moslehi, Michelle Rosenzwajg, Joe-Elie Salem

Clinical/translational cancer immunotherapy

Original research: Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity (22 April, 2022)
Ssu-Hsueh Tseng, Max A Cheng, Emily Farmer, Louise Ferrall, Yu Jui Kung, Brandon Lam, Ling Lim, T-C Wu, Chien-Fu Hung
Original research: Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion (15 April, 2022)
Camille Le Gall, Anna Cammarata, Lukas de Haas, Iván Ramos-Tomillero, Jorge Cuenca-Escalona, Kayleigh Schouren, Zacharias Wijfjes, Anouk M D Becker, Johanna Bödder, Yusuf Dölen, I Jolanda M de Vries, Carl G Figdor, Georgina Flórez-Grau, Martijn Verdoes
Original research: Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study (20 April, 2022)
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Jonathan Zalevsky, Arlene O Siefker-Radtke, Michael E Hurwitz
Original research: Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa (13 April, 2022)
Yo-Ting Tsai, Julius Strauss, Nicole J Toney, Caroline Jochems, David J Venzon, James L Gulley, Jeffrey Schlom, Renee N Donahue
Original research: Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial (12 April, 2022)
Charu Aggarwal, Amy Prawira, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan P Zandberg, Arash Rezazadeh Kalebasty, Victoria Atkinson, Alex A Adjei, Mahesh Seetharam, Ariel Birnbaum, Andrew Weickhardt, Vinod Ganju, Anthony M Joshua, Rosetta Cavallo, Linda Peng, Xiaoyu Zhang, Sanjeev Kaul, Jan Baughman, Ezio Bonvini, Paul A Moore, Stacie M Goldberg, Fernanda I Arnaldez, Robert L Ferris, Nehal J Lakhani
Original research: Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer (6 April, 2022)
Alexey Revenko, Larissa S Carnevalli, Charles Sinclair, Ben Johnson, Alison Peter, Molly Taylor, Lisa Hettrick, Melissa Chapman, Stephanie Klein, Anisha Solanki, Danielle Gattis, Andrew Watt, Adina M Hughes, Lukasz Magiera, Gozde Kar, Lucy Ireland, Deanna A Mele, Vasu Sah, Maneesh Singh, Josephine Walton, Maelle Mairesse, Matthew King, Mark Edbrooke, Paul Lyne, Simon T Barry, Stephen Fawell, Frederick W Goldberg, A Robert MacLeod
Original research: Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials (5 April, 2022)
Yoon-Koo Kang, Martin Reck, Paul Nghiem, Yan Feng, Gregory Plautz, Hye Ryun Kim, Taofeek K Owonikoko, Narikazu Boku, Li-Tzong Chen, Ming Lei, Han Chang, Wen Hong Lin, Amit Roy, Akintunde Bello, Jennifer Sheng
Original research:
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
(5 April, 2022)
Minyu Wang, Soroor Zadeh, Angela Pizzolla, Kevin Thia, David E Gyorki, Grant A McArthur, Richard A Scolyer, Georgina Long, James S Wilmott, Miles C Andrews, George Au-Yeung, Ali Weppler, Shahneen Sandhu, Joseph A Trapani, Melissa J Davis, Paul Joseph Neeson
Original research: Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial (3 April, 2022)
Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, Xiangcheng Li, Feng Cheng, Ke Wang, Feng Zhang, Chuanyong Zhang, Donghua Li, Jinhua Song, Hui Zhang, Jie Zhao, Aihua Yao, Xiaofeng Wu, Chen Wu, Guwei Ji, Xisheng Liu, Feipeng Zhu, Lang Qin, Xuan Xiao, Zhenhua Deng, Xiangyi Kong, Si Li, Yangyang Yu, Wenjing Xi, Wanglong Deng, Chuang Qi, Hanyuan Liu, Liyong Pu, Ping Wang, Xuehao Wang

Hypothesis

Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment (5 April, 2022)
Dali Tong

Immune cell therapies and immune cell engineering

Original research:
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8⁺ T cell cytotoxicity over BEMPEG+RT
(20 April, 2022)
Annah S Rolig, Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L Redmond
Original research: TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation (5 April, 2022)
Audrey Moatti, Anais Debesset, Caroline Pilon, Asma Beldi-Ferchiou, Mathieu Leclerc, Rabah Redjoul, Frederic Charlotte, Nhu Hanh To, Adeline Bak, Yazid Belkacemi, Benoît Laurent Salomon, Fadi Issa, David Michonneau, Sebastien Maury, José Laurent Cohen, Allan Thiolat

Immunotherapy biomarkers

Original research: High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC (27 April, 2022)
Joan Frigola, Caterina Carbonell, Patricia Iranzo, Nuria Pardo, Ana Callejo, Susana Cedres, Alex Martinez-Marti, Alejandro Navarro, Mireia Soleda, Jose Jimenez, Javier Hernandez-Losa, Ana Vivancos, Enriqueta Felip, Ramon Amat
Original research: Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis (25 April, 2022)
Omkar Chaudhary, Diane Trotta, Kaicheng Wang, Xun Wang, Xiuping Chu, Chip Bradley, Jason Okulicz, Ryan C Maves, Karl Kronmann, Christina M Schofield, Jason M Blaylock, Yanhong Deng, Kurt A Schalper, Susan M Kaech, Brian Agan, Anuradha Ganesan, Brinda Emu
Original research: Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target (5 April, 2022)
Haizhou Wang, Yabo Zhou, Yangyang Zhang, Shilin Fang, Meng Zhang, Haiou Li, Fei Xu, Lan Liu, Jing Liu, Qiu Zhao, Fan Wang
Original research: Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center (1 April, 2022)
Evan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, Martina Bradic, Daniel Kashani, Allison L Richards, Mark Donoghue, Ciara M Kelly, Benjamin Nacev, Jason E Chan, Ping Chi, Mark A Dickson, Mary L Keohan, Mrinal M Gounder, Sujana Movva, Viswatej Avutu, Katherine Thornton, Ahmet Zehir, Anita S Bowman, Samuel Singer, William Tap, Sandra D’Angelo

Oncolytic and local immunotherapy

Original research: OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study (5 April, 2022)
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert Andtbacka, Jun Guo

Review

Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time? (25 April, 2022)
Syrine Abdeljaoued, Sara Arfa, Marie Kroemer, Myriam Ben Khelil, Angélique Vienot, Bruno Heyd, Romain Loyon, Alexandre Doussot, Christophe Borg
JAK inhibitors and COVID-19 (22 April, 2022)
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology (20 April, 2022)
Yanchen Zhou, Hweixian L Penny, Mark A Kroenke, Bianca Bautista, Kelly Hainline, Lynette S Chea, Jane Parnes, Daniel T Mytych
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy (15 April, 2022)
Jennifer Sun, Chaelee Park, Nicole Guenthner, Shannon Gurley, Luna Zhang, Berit Lubben, Ola Adebayo, Hannah Bash, Yixuan Chen, Mina Maksimos, Barbara Muz, Abdel Kareem Azab
The use of oncolytic virotherapy in the neoadjuvant setting (12 April, 2022)
Raquela J Thomas, Eric Bartee
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy (4 April, 2022)
Eugene Y Chiang, Ira Mellman
To go or not to go? Biological logic gating engineered T cells (4 April, 2022)
Rebecca C Abbott, Hannah E Hughes-Parry, Misty R Jenkins

Main menu

Table of contents

April 2022 - Volume 10 - 4

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Hypothesis

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

April 2022 - Volume 10 - 4

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Hypothesis

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Review

Correction